(Press-News.org) COLUMBUS, Ohio – A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.
In the first clinical trial of this drug in humans, nemtabrutinib (pronounced Nem-ta-BROO-ti-nib) was effective in three-fourths of cancer patients tested, without severe side effects. The results of the trial were published in the journal Cancer Discovery.
Hematologist and study lead investigator Jennifer Woyach, MD, notes that about half a dozen drugs are available to treat these B-cell cancers. Although most patients respond to these drugs initially, over time, many patients experience disease progression.
“Blood cancers that have relapsed after initial treatments can be difficult to treat, and even with our effective medications, some patients run out of standard treatment options. In this trial, nemtabrutinib looks very promising for patients whose cancer has progressive after other treatments.” said Woyach, who is co-leader of the Leukemia Research Program at the OSUCCC – James.
How this drug therapy works
When an antigen, such as a virus or bacteria, enters the bloodstream, it triggers a set of signals in B-cells to produce antibodies. In some people, said Woyach, this process goes haywire. Instead of fighting infections, the B-cells begin to divide uncontrollably, resulting in cancer. Drugs against B-cell cancers work by binding to a key enzyme, called Bruton's tyrosine kinase (BTK). This enzyme is involved in the signaling process. The drugs block the action of the enzyme, and as a result, the abnormal B-cells die.
In many patients, this effect is temporary with available drugs. Over time, the BTK enzyme to which the drugs bind mutates so they can no longer stop its action. Soon, the cancer returns. Nemtabrutinib was designed to bind to BTK even in the presence of common mutations that make other BTK inhibitors stop working. It also binds to a number of proteins besides BTK that are important in B cell cancers. These two properties made this drug very appealing to study in this patient population.
Study methods and results
The researchers tested the new drug on 47 patients who have had at least two prior therapies for their blood cancer. Over half of these patients had relapsed CLL, while the others had NHL. The researchers gave these patients one pill of nemtabrutinib every day, with different doses along the trial. They observed the patients’ response to the drug over time and monitored them for side effects.
The study found more than 75% of the patients with relapsed CLL responded to the drug, at an optimal dose of 65mg. These included patients who had mutations in BTK. Most patients remained cancer free for at least 16 months during the trial. While all patients experienced some side effects—which is common with chemotherapeutic drugs—many of these were minor and manageable, proving that the drug was also very safe.
“The drug is being moved to larger and more definitive trials, where it will be compared against other standard-of-care drugs, and in combination with other active medications,” said Woyach.
Blood cancer kills one person every nine minutes in the United States, and every three minutes, someone is diagnosed with the disease. The blood cancers investigated in this trial affect a specific type of white blood cell, called a B lymphocyte, which is a cell that is responsible for producing antibodies and fighting infections. CLL is the most common leukemia making up a quarter of leukemia cases among adults, and NHL accounts for 4% of all cancers in the United States.
This clinical trial was supported by Arqule Inc, a fully owned subsidiary of Merck & Co. Other researchers involved in this study were Seema Bhat, Sean Reiff, Elizabeth Muhowski and Lyndsey Szuszkiewicz from OSUCCC - James, Deborah Stephens from Huntsman Cancer Institute, Ian Flinn from Sarah Cannon Research Institute, Ronald Savage, Brian Schwartz, Sudharshan Eathiraj, Lindsey Granlund, and Feng Chai from ArQule, Inc., Wayne Wang from Veristat LLC, Razi Ghori and Mohammed Farooqui from Merck & Co., and John C. Byrd from University of Cincinnati College of Medicine.
To learn more about blood cancer treatment and clinical trials at the OSUCCC – James, visit cancer.osu.edu.
###
END
First in human trial of new drug raises hopes for patients with relapsed blood cancer
2023-11-06
ELSE PRESS RELEASES FROM THIS DATE:
A cutting-edge approach to tackling pollution in Houston and beyond
2023-11-06
With its notoriously hot and humid climate and robust industrial environment, Houston is one of the most ozone-polluted cities in the United States. Now, a University of Houston research team is integrating the power of machine learning (ML) with innovative analysis techniques to pinpoint the city’s air pollution sources more accurately.
While the ozone layer in the stratosphere protects the Earth, and us, from the harmful rays of the sun, it’s also a major pollutant that can be harmful to human health when it’s closer to the ground. Long-term exposure to surface ozone can cause difficulty breathing, worsen asthma and increase the ...
The last turn of ‘Ezekiel’s Wheel’ honors a Yale-affiliated fossil hunter
2023-11-06
New Haven, Conn. — The mystery of Ezekiel’s Wheel — the extinct sea creature, not the Biblical vision — may have taken its final turn, thanks to Yale paleontologists.
In so doing, the researchers have also finally put a scientific name to the favorite fossil of a beloved amateur fossil hunter.
Samuel J. Ciurca Jr., who died in 2021, was a curatorial affiliate of the Yale Peabody Museum for many years. He collected tens of thousands of fossils, primarily from the Silurian rocks of upstate New York and southern Ontario, Canada.
He donated more than 11,000 ...
STEM Career Days boost high school students’ career aspirations in STEM fields, MU study finds
2023-11-06
COLUMBIA, Mo. – A new study at the University of Missouri — in partnership with Harvard-Smithsonian researchers — shows that when colleges host ‘STEM Career Days,’ the students who attend are far more likely to pursue a career in a STEM (Science, Technology, Engineering and Math) related field.
The findings not only highlight the benefits of college recruiters introducing high school students to STEM-related opportunities, but they can also help increase and diversify ...
Ochsner Health and Chevron partner for a third consecutive year to offer smoking cessation and education program
2023-11-06
NEW ORLEANS, La. – Chevron and Ochsner Health continue to offer their Lung Cancer Awareness, Education and Prevention Program for a third consecutive year thanks to a $50,000 donation from Chevron. The program will be offered in Jefferson Parish for the first time and continue to reach community members in St. Tammany, East Baton Rouge, West Baton Rouge, Ascension, St. Charles, Terrebonne, and Lafourche parishes.
Ochsner Health and Chevron formed a key partnership for the Lung Cancer Awareness, Education and Prevention Program to improve lung health and overall wellness. ...
Patients more likely to lose weight if physicians offer advice using optimistic tone
2023-11-06
Embargoed for release until 5:00 p.m. ET on Monday 6 November 2023
Annals of Internal Medicine Tip Sheet
@Annalsofim
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------
1. Patients more likely to lose weight if physicians offer advice using optimistic tone
Abstract: ...
Deploying sensor nets to measure ocean CO2 and pH from the surface to the depths
2023-11-06
Researchers at the University of Pittsburgh Swanson School of Engineering, in collaboration with the National Energy Technology Laboratory, are among 11 projects in eight states selected to receive a combined $36 million to accelerate the development of marine carbon dioxide removal (mCDR) capture and storage technologies.
The funding from the U.S. Department of Energy Advanced Research Projects Agency-Energy (ARPA-E) is part of the ARPA-E Sensing Exports of Anthropogenic Carbon Through Ocean ...
Passion for vascular disease research yields $5 million in NIH funding for Yabing Chen
2023-11-06
BIRMINGHAM, Ala. – Yabing Chen, Ph.D., has been awarded two National Institutes of Health grants totaling more than $5 million to further her research into vascular diseases ranging from hardening of the arteries to dementia.
Vacuolar calcification, which leads to the hardening of blood vessels and increased vascular stiffness, is a hallmark of the aging process in the cardiovascular system. As early as the mid-1600s, physician Thomas Sydenham noted that “a man is as old as his arteries.” Chen expands that to include two different disease processes. “I like ...
Study shines light on the health of American moms in the year after birth
2023-11-06
Maternal mortality in the U.S. is on the rise and more than half of maternal deaths occur in the postpartum year. A study by Columbia University Mailman School of Public Health and the School of Social Work provides insights into the challenges that birthing people face in the year after birth - both medical and social - which could be drivers of postpartum morbidity and mortality. The study is the first large scale and representative survey of postpartum health ever conducted in the U.S. The findings ...
Firearm injuries among children and adolescents lead to huge mental and behavioral health consequences
2023-11-06
BOSTON – The alarming increase in firearm injuries to children and adolescents in the United States has taken an enormous mental and behavioral health toll on victims, survivors, and their families, with ripple effects on the economy and health care spending, researchers from Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) have found.
In a study published in the November Issue Health Affairs, the team cited the substantial opportunities for improvements in clinical practice for survivors of gun violence and their family members, such as improved screening for mental and behavioral health needs, as well as enhanced educational programs for the ...
The health and economic toll of gun violence in youth
2023-11-06
Since 2020, firearms have been the number one cause of death among children and teens in the United States, surpassing even car accidents, according to the U.S. Centers for Disease Control and Prevention. In 2022 more than 4,500 young people died from firearm injuries.
In addition to those who die, thousands more young people survive firearm injuries each year. The harm from these injuries reverberates for months and years, with ripple effects on parents and siblings, according to the findings of a new study published Nov. 6 in the November issue of Health Affairs.
“The unspeakable ...